Novocure (NVCR) Announces Enrollment of First Patient in METIS Trial
Tweet Send to a Friend
Novocure (Nasdaq: NVCR) announced that the first patient has been enrolled in the METIS trial, a phase 3 pivotal trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
